What question did this study set out to answer?

To determine whether standardizing materials, laboratory protocols, and interpretive criteria for the hemagglutination inhibition (HAI) assay can achieve high reproducibility across multiple research laboratories.

March 1, 2016Clinical and Vaccine ImmunologyOpen Access

Standardization of Hemagglutination Inhibition Assay for Influenza Serology Allows for High Reproducibility between Laboratories

View Full Paper

Ask AI

Bookmark

Authors

MZMary ZacourParaza Pharma (Canada)BWBrian J. WardMcGill University Health Centre ABAngela BrewerMcGill University Health Centre

Discussion

Member takes

Implication

Multicenter laboratory study demonstrates high reproducibility of hemagglutination inhibition titers in human serum panels, indicating reliable cross-trial vaccine evaluations are achievable.

Key Points

To determine whether standardizing materials, laboratory protocols, and interpretive criteria for the hemagglutination inhibition (HAI) assay can achieve high reproducibility across multiple research laboratories.
Standardized HAI materials, methods, and interpretive criteria across five geographically dispersed laboratories within a multidisciplinary influenza research network.
Repeatedly tested standardized panels of human serum samples across participating sites to quantify intralaboratory precision and interlaboratory agreement relative to consensus and reference laboratory titers.
Within-laboratory duplicate precision was 99.8% (99.2% to 100%) and assay reproducibility across repeated runs was 98.0% (93.3% to 100%).
Titers were within 2-fold of consensus values for 98.9% (95% to 100%) of samples and within 2-fold of reference laboratory data for 94.3% (85% to 100%), with low-titer samples displaying the greatest variability.
Classification of seroprotection (titer ≥ 40) was accurate in 93.6% of cases relative to consensus and in 89.5% relative to the reference laboratory.

Cite This Study

Zacour et al. (2016) studied this question.

synapsesocial.com/papers/6a01da990cec8eebbd5cb128 https://doi.org/10.1128/cvi.00613-15

View Full Paper

Ask AI

Bookmark

Implication

Multicenter laboratory study demonstrates high reproducibility of hemagglutination inhibition titers in human serum panels, indicating reliable cross-trial vaccine evaluations are achievable.

Standardization of Hemagglutination Inhibition Assay for Influenza Serology Allows for High Reproducibility between Laboratories

Discussion

Member takes

Implication

Key Points

Cite This Study

Standardization of Hemagglutination Inhibition Assay for Influenza Serology Allows for High Reproducibility between Laboratories

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider